The US Food and Drug Administration’s three- to five-year estimate for a rulemaking on lawful use of cannabidiol in dietary supplements rattled a House subcommittee chairwoman already disappointed in the agency’s oversight of the exploding market.
FDA Gets Message In Congress' First Cannabis Policy Hearing: Deliver CBD Regulation
During first-ever congressional hearing on federal policies for lawful use of cannabis, House Energy and Commerce Health Subcommittee Chairwoman Anna Eschoo says with $2m appropriated to develop a regulation on CBD’s use in non-drug products during, FDA should deliver.
More from Legislation
• By
Changes established in West Virginia and proposed in numerous other states gained momentum after Trump was elected to his second term as president and nominated Kennedy to head HHS.
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
At a recent European Parliament event, IPA Europe called on EU institutions to “prioritize proportional and coherent rules on the European probiotic food and food market, to ensure EU policies are fit for competitiveness.”
• By
“We have made significant strides in finding new ways to return money to consumers, but a fix to our 13(b) authority is badly needed,” says Sam Levine.
More from Policy & Regulation
• By
FDA says “extension affords covered entities the additional time necessary to ensure complete coordination across the supply chain in order to fully implement the final rule’s requirements—ultimately providing FDA and consumers with greater transparency and food safety.”
• By
HBW Insight speaks to AESGP director general Jurate Švarcaite about what's on the agenda for the upcoming 61st AESGP Annual Meeting, which will take place in Warsaw, Poland, between 2-4 June. Highlights include the role of prevention in self-care, discussions about how regulators will ensure the competitiveness of European industry on the world stage and incoming changes to sustainability legislation.
• By
CRN petition argues against general preclusion while NPA petition addressed specifically FDA’s wielding of the provision to prohibit the use of NMN supplements available in US. “FDA has acknowledged that they really can't answer one without answering. The two are inextricably linked,” says CRN CEO Steve Mister.